NO20051545L - Ostrogenerstatningsregime - Google Patents

Ostrogenerstatningsregime

Info

Publication number
NO20051545L
NO20051545L NO20051545A NO20051545A NO20051545L NO 20051545 L NO20051545 L NO 20051545L NO 20051545 A NO20051545 A NO 20051545A NO 20051545 A NO20051545 A NO 20051545A NO 20051545 L NO20051545 L NO 20051545L
Authority
NO
Norway
Prior art keywords
east
tadiol
dose
ostrogenerstatningsregime
alloster
Prior art date
Application number
NO20051545A
Other languages
English (en)
Norwegian (no)
Inventor
Robert F Casper
Gideon Kopernik
Zeev Shoham
Original Assignee
Zeev Shoham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeev Shoham filed Critical Zeev Shoham
Publication of NO20051545L publication Critical patent/NO20051545L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20051545A 2002-08-28 2005-03-23 Ostrogenerstatningsregime NO20051545L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40633102P 2002-08-28 2002-08-28
PCT/CA2003/001325 WO2004019954A1 (en) 2002-08-28 2003-08-28 Estrogen replacement regimen

Publications (1)

Publication Number Publication Date
NO20051545L true NO20051545L (no) 2005-03-23

Family

ID=31978284

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051545A NO20051545L (no) 2002-08-28 2005-03-23 Ostrogenerstatningsregime

Country Status (25)

Country Link
US (1) US8946198B2 (sr)
EP (1) EP1539184B1 (sr)
JP (1) JP2005538150A (sr)
KR (1) KR20050059092A (sr)
CN (1) CN1678324A (sr)
AT (1) ATE345804T1 (sr)
AU (1) AU2003264203A1 (sr)
BR (1) BR0313921A (sr)
CA (1) CA2495330A1 (sr)
CY (1) CY1106019T1 (sr)
DE (1) DE60309895T2 (sr)
DK (1) DK1539184T3 (sr)
ES (1) ES2277139T3 (sr)
HR (1) HRP20050291A2 (sr)
IL (1) IL166585A0 (sr)
MX (1) MXPA05002294A (sr)
NO (1) NO20051545L (sr)
NZ (1) NZ538342A (sr)
PL (1) PL374762A1 (sr)
PT (1) PT1539184E (sr)
RS (1) RS20050184A (sr)
RU (1) RU2340345C2 (sr)
UA (1) UA82851C2 (sr)
WO (1) WO2004019954A1 (sr)
ZA (1) ZA200501274B (sr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015138668A1 (en) * 2014-03-12 2015-09-17 Warner Chilcott Company, Llc Low-dose estradiol cream
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT3701944T (lt) 2015-06-18 2022-04-11 Estetra Srl Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
JP6813150B2 (ja) 2015-06-18 2021-01-13 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
ES2671160T3 (es) 2015-06-18 2018-06-05 Mithra Pharmaceuticals S.A. Unidad de dosificación orodispersable que contiene un componente estetrol
PL3310345T3 (pl) 2015-06-18 2021-10-18 Estetra Sprl Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol
MX2017016823A (es) 2015-06-22 2018-03-12 Lipocine Inc Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
SG11202009725XA (en) 2018-04-19 2020-11-27 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US4900734A (en) * 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
NZ226316A (en) * 1987-09-24 1991-10-25 Jencap Research Ltd Pharmaceutical contraceptive preparations and packages containing from 20-35 unit dosages comprising an estrogen and a progestin; the unit dosages having alternating estrogen and progestin dominance
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5382873A (en) * 1991-12-04 1995-01-17 U.S. Philips Corporation High-pressure discharge lamp with incandescing metal droplets
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
JP3534775B2 (ja) * 1995-06-07 2004-06-07 オーソ―マクニール ファーマシューティカル，インコーポレイテッド １７−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法
US6506390B2 (en) * 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10100911A1 (de) * 2001-01-11 2002-08-01 Schering Ag Verfahren zur Hormonersatztherapie und dessen Darreichungsform

Also Published As

Publication number Publication date
WO2004019954A1 (en) 2004-03-11
CA2495330A1 (en) 2004-03-11
ATE345804T1 (de) 2006-12-15
RU2340345C2 (ru) 2008-12-10
CY1106019T1 (el) 2011-04-06
RU2005108977A (ru) 2005-10-10
PL374762A1 (en) 2005-10-31
RS20050184A (sr) 2007-11-15
UA82851C2 (en) 2008-05-26
PT1539184E (pt) 2007-02-28
NZ538342A (en) 2007-08-31
CN1678324A (zh) 2005-10-05
EP1539184A1 (en) 2005-06-15
DE60309895D1 (de) 2007-01-04
DE60309895T2 (de) 2007-10-18
EP1539184B1 (en) 2006-11-22
DK1539184T3 (da) 2007-03-19
MXPA05002294A (es) 2005-09-12
US8946198B2 (en) 2015-02-03
HRP20050291A2 (en) 2005-10-31
ES2277139T3 (es) 2007-07-01
ZA200501274B (en) 2006-08-30
KR20050059092A (ko) 2005-06-17
IL166585A0 (en) 2006-01-15
BR0313921A (pt) 2005-07-19
US20060089337A1 (en) 2006-04-27
AU2003264203A1 (en) 2004-03-19
JP2005538150A (ja) 2005-12-15

Similar Documents

Publication Publication Date Title
NO20051545L (no) Ostrogenerstatningsregime
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
NO20073065L (no) Injiserbare nanopartikulaere olanzapinformuleringer
ATE459357T1 (de) Kombinationen zur behandlung von multiplem myelom
IL214325A0 (en) Humanized anti-cmet antagonists
WO2005048935A3 (en) Methods of modulating immunity
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
ZA200606844B (en) Use for interleukin-33 (IL33) and the IL-33 receptor complex
IL183607A0 (en) Composition for proteasome inhibition
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
SG148198A1 (en) Methods and reagents for the treatment of inflammatory disorders
GEP20247585B (en) Furoindazole derivatives
NZ752918A (en) Treatment of prostate cancer
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
MX2010008220A (es) Metodos que usan compuestos inmunomoduladores para modular nivel de cd59.
MXPA05013478A (es) Combinaciones terapeuticas.
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
MX2023001571A (es) Terapia combinada con antagonistas del receptor de adenosina.
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
MX2022005407A (es) Tratamiento de trastornos hepaticos.
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application